Description
PrymaLab · Research use only
Preloaded Autoinjector | Cartalax | 3ml Pen | 20mg
Cartalax (Ala-Glu-Asp) at 0.67% w/v: 20 mg in a preloaded 3 mL pen
Cartalax, the Khavinson tripeptide Ala-Glu-Asp (AED, coded T-31), is supplied here already dissolved in a preloaded pen: 20 mg in a 3 mL cartridge of bacteriostatic water, 0.67% w/v by the safety data sheet. Every study of AED in the references for this page used cultured cells or tissue explants, including human skin fibroblasts and kidney tissue from young and old rats, and most of the papers came from Khavinson’s own group.
Specifications
| Property | Value |
|---|---|
| Compound | Cartalax Ala-Glu-Asp (AED; T-31); Khavinson cartilage peptide bioregulator |
| CAS number | 85806-95-7 |
| Molecular formula | C12H19N3O8 |
| Theoretical mass | 333.3 Da |
| Sequence / structure | H-AED-OH (3 residues; free N- and C-termini) |
| Contents | Cartalax: 20 mg per 3 mL pen (0.67% w/v) |
| Form | Sterile aqueous solution in bacteriostatic water (0.9% benzyl alcohol), supplied in a 3 mL glass cartridge inside a preloaded autoinjector pen fitted with a needle |
| Storage, sealed | Store at 2–8 °C in the original carton, protected from light |
| Safety data sheet | PL-SDS-033 |
What is in the pen
The 3 mL cartridge holds sterile solution containing 20 mg of the same H-AED-OH sold as freeze-dried powder in the Cartalax 20 mg vial: about 6.7 mg/mL, or roughly 60 µmol per pen. The solvent is bacteriostatic water with 0.9% benzyl alcohol as preservative. On the safety data sheet the peptide is unclassified; the benzyl alcohol is labelled harmful if swallowed or inhaled, a serious eye irritant and a possible skin sensitiser.
Store the pen in its carton at 2 to 8 °C, protected from light and capped between uses. It must not freeze, and a solution that has frozen, discoloured or clouded should be thrown away. Peptide pen vs vial compares the two formats in general.
What the research covers
AED’s best-documented effects come from aging cell cultures. In human skin fibroblasts kept in culture until they aged, AED, like KE, KED and AEDG, lowered MMP-9 and raised the proliferation marker Ki-67 and CD98hc, and AED and AEDG also held back caspase-dependent apoptosis1. In a human mesenchymal stem cell line aged by passaging or by stationary culture, AED, KED and KE raised IGF1 expression 3.5 to 5.6-fold and stimulated NFκB2.
These studies exposed cells to the peptide in culture medium. None measured AED in a stored solution or reports how long it stays intact in water, so for the pen the safety data sheet is the guidance on storage. There are no animal or human data in these abstracts and no cartilage experiment, despite the compound’s cartilage label. Most of the papers appeared in Bulletin of Experimental Biology and Medicine, a Russian journal published in English. The Cartalax (T-31) guide covers the full literature, including the rat kidney work.
How each lot is tested
Every lot is tested in PrymaLab’s own laboratory in Ashland, Kentucky before release: RP-HPLC for purity, LC-MS for identity, Karl Fischer titration for water, LAL for endotoxin and USP <71> for sterility. Published certificates are listed on the results page and can be checked by number and key on the verify page. The certificate covers the peptide lot used to fill the pen, not the finished solution. These are in-house results from PrymaLab Analytical, not an independent test, and the lab is not accredited to ISO 17025. The third-party testing guarantee on this page still applies: if any independent laboratory finds the wrong compound, or less than the stated purity or amount, the order is refunded and the cost of the test is reimbursed.
Frequently asked questions
What is the difference between the Cartalax pen and the vial?
The peptide is the same Ala-Glu-Asp and the amount is the same, 20 mg. The vial is freeze-dried and kept at −20 °C until dissolved; the pen is a 6.7 mg/mL solution in bacteriostatic water stored at 2 to 8 °C. Only the vial lets the lab choose solvent and concentration.
Which lot does the pen's certificate describe?
The certificate describes the batch of Cartalax peptide used to fill the pen, as tested in PrymaLab's own laboratory, rather than the solution in the cartridge. Find it by lot number on the testing results page and confirm it on the verify page.
Does the published research apply to the pen?
Only as background on the peptide. The AED studies exposed cultured cells to it and did not test any stored solution, so they say nothing about how the pen's contents keep. The storage limits on the safety data sheet are what to follow.
Is the Cartalax pen intended for people?
No. It is a laboratory research product, not approved for human or veterinary use by the FDA or any other authority, and it must not be used in people or animals.
References
- Lin'kova NS, Drobintseva AO, Orlova OA, et al. Peptide Regulation of Skin Fibroblast Functions during Their Aging In Vitro. Bull Exp Biol Med. 2016;161(1):175-8. DOI · PubMed
- Ashapkin V, Khavinson V, Shilovsky G, et al. Gene expression in human mesenchymal stem cell aging cultures: modulation by short peptides. Mol Biol Rep. 2020;47(6):4323-4329. DOI · PubMed
Research use only
For laboratory research use only. This product is not a drug, food, cosmetic or dietary supplement, is not approved by the FDA or any comparable authority for human or veterinary use, and must not be given to people or animals. It is sold to qualified researchers and institutions, and the buyer is responsible for lawful handling and disposal.
Reviews
There are no reviews yet.